



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q2

2023

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO

August 3, 2023

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q2 2023

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Sales & EBITDA above prior year & guidance confirmed



Sales and EBITDA above prior year with different impact from segments



Substantial growth in the human nutrition market



Operating cash flow and free cash flow strongly positive and much higher compared to last year



Climate roadmap has been approved




Guidance confirmed with sales at lower end and EBITDA at upper end



Additional expansion of Creapure® capacities on schedule with expected completion in fall 2023


“VERBUND” SYSTEM – FULLY INTEGRATED BUSINESS MODEL

Ability to adapt production to meet changing end market needs



“VERBUND” SYSTEM – FULLY INTEGRATED BUSINESS MODEL

Health & Nutrition



Premium brand for creatine monohydrate as a food supplement in sports nutrition



Dietary supplement with pure creatine





Creatine for health and food applications





KREATIN IN SPORT, FITNESS, HEALTH & FOOD

Creatine boosts body energy in many areas








SPORT



FITNESS



HEALTH



FOOD

OUR MARKETS

| | Sport | Fitness | Health | Food |
|-----|-----------|----------|--------------|------|
| B2B | Creapure® | | Creavitalis® | |
| B2C | | LIVADUR® | | |



WHY CREAVITALIS®

- Tailor made creatine product for health and food applications
- Specific marketing to approach new markets
- Micronization and tight analytical control to respond to consumer expectations
- Scientific studies to support new uses of creatine




Phosphocreatine plays an essential role in the cellular energy metabolism.

Cellular energy is needed for supporting all energy intensive body functions.

FOCUS AREAS OF CREATINE




Female Health



Male Fertility



Energy



Recovery



Cardiovascular



Brain & Cognitive Functions



Fatigue Symptoms

FINANCIAL OVERVIEW

Positive development in a challenging environment



| Alzchem Group | Q2 2022 | Q2 2023 | yoy % | 2022 1 - 6 | 2023 1 - 6 | yoy % |
|---------------------------|------------|------------|---------|---------------|---------------|---------|
| SALES (in M€) | 140.4 | 126.6 | -9.9% | 269.8 | 277.0 | +2.7% |
| EBITDA (in M€) | 17.8 | 17.9 | +0.4% | 34.9 | 36.8 | +5.5% |
| EBITDA margin (in %) | 12.7% | 14.1% | +1.4 pp | 12.9% | 13.3% | +0.4 pp |
| Earnings per Share (in €) | 0.95 | 0.71 | -25.5% | 1.71 | 1.46 | -14.6% |

- Sales in the first half EUR 7.2 million above previous year with different development in the segments
- Substantial growth in the human nutrition market; continued stable development in the steel and pharmaceutical industries and in the automotive sector; declining demand for fertilizers
- Concentration on high-margin products and partial price declines led to a drop in volumes in the 2nd quarter; but EBITDA stable as sales follow cost.

| SALES ANALYSIS | DELTA Q2 | DELTA 01 - 06 |
|-------------------|-------------|------------------|
| Volume | -18.8% | -12.8% |
| Price | 9.3% | 15.1% |
| Currency | -0.4% | 0.4% |

AGENDA – ANALYST PRESENTATION Q2 2023

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)




Volume reductions but increased EBITDA

SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

| | DELTA Q2 | DELTA 01 - 06 |
|----------|-------------|------------------|
| Volume | - 26.9% | - 25.5% |
| Price | + 6.5% | + 15.1% |
| Currency | - 0.2% | + 0.0% |

COMMENTS

- Q2/2023 Sales ~ 21 % below previous year
- Persistently high energy prices led to necessary high sales prices in agricultural and pharmaceutical sector which cannot keep pace with Asian competitors
- Metallurgic sector on previous year´s level but with lower prices following price formulas
- Slight relief of energy and raw material costs supports earnings
- EBITDA-Margin of 5,2 % in Q2/2023 (previous year 1,5 %)



CREAMINO

Dormex[®]

Bioselect[®]

DYHARD[®]

Creapure[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)




Sales increase in first half of 2023, lower volumes affect EBITDA


SALES



EBITDA



SALES



EBITDA



SALES ANALYSIS

| | DELTA Q2 | DELTA 01 - 06 |
|----------|-------------|------------------|
| Volume | - 15.4% | - 4.6% |
| Price | + 11.9% | + 16.3% |
| Currency | -0.5% | + 0.6% |

COMMENTS

- Sales increase in first half year with strong growth in human nutrition with Creapure®
- Stable development in all other products except BioSelect®, which suffers from high stock levels and a registration delay at one customer
- Sales in Q2/2023 ~ 4 % lower than in Q2/2022
- Demand slowdown in many areas
- EBITDA-Margin in Q2/2023 +20,4 % (vs. Q2/2022 +21,4 %)






OTHER & HOLDING

The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)



Development of services in line with 2022 and cost bases



COMMENTS


- Q2/2023 sales ~17 % above previous year's level based on pass-through of cost increases in pricing and higher grid fees in energy supply services
- Higher network charges and lower power supply losses have a positive impact on EBITDA-Margin

BALANCE SHEET (in M€)


Stable balance sheet development with improved equity ratio



ASSETS



LIABILITIES




- Decrease in balance sheet total of 3.6 M€ to 419.2 M€; current and non-current assets developed slightly in opposite directions
- Cautious investments strategy resulted in depreciation being higher than capital expenditure and decrease in non-current assets
- Increase in inventories reflects partial stock increases as a preparation for scheduled maintenance downtime in Q3
- Trade receivables mainly stable compared to last reporting date; no major late payments and no changes in payment behavior

- Equity ratio developed from 34.5% to 35.4% due to offsetting effects:
 - Result for the period (+15.0 M€)
 - Increase in pension obligation due to slight decrease in pension interest rates (-1.1 M€ after deduction of deferred taxes)
 - Dividend payment (-10.7 M€)
- Refinancing of 30.0 M€ from current to non-current liabilities in February 2023
- Regular loan and lease repayments of 5.9 M€ decreased non-current liabilities
- Strong free cashflow used to further reduce current liabilities

CASHFLOW (in M€)

Strong operating and free cashflow; reduction of short-term financing



- Very strong cashflow from operating activities in first half of 2023 (+ 39.8 M€) due to strict working capital management after negative cashflow in first half 2022 -> improvement of 57.0 M€
- Cashflow from investing activity characterized by the cautious investment policy in first half year 2023. Nevertheless no slowdown in investing in capacity expansions of the Creapure®-plant and renewal of the grid operations
- Free cashflow also strongly increased compared to prior year -> increase of 63.4 M€; all investments were financed by operating cashflow and additional amounts used to reduce short-term financing lines
- Cashflow from financing activities was marked by the restructuring of financing loans from current to non-current (30.0 M€). Additional reduction of short-term financing lines (14.0 M€), scheduled repayment of long-term bank loans (5.9 M€) and pay out dividends to our shareholders (10.7 M€)

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers and sustainability



IMPROVEMENT

- Raw material price increases at least passed on to the market
- Flexibilization of production
- Reduce waste via development of new processes (Creapure®)

GROWTH

- Volume growth and full utilization of realized capex (Creapure®, Creamino®, Nitralz®, SiliconNitride)
- Establish Eminex® as a methane prevention product
- Initiate and decide on capacity expansion of MultiPurpose plants

SUSTAINABILITY


- Vision 0 accidents and 0 waste
- Implementation of climate roadmap (with reduction of CO₂ and water footprint (-10%))
- Implement EU Taxonomy Regulation and CSRD in an audit-ready manner

OUTLOOK 2023 (in M€)


Outlook from 2022 confirmed, different development in ranges



SALES



EBITDA



COMMENTS

- Outlook 2023 from annual statements 2022 confirmed
- Group sales are expected to end up at the lower end of the forecasted range
 - Slight reduction of production input costs required a partial pass-through in product pricing leading to lower overall sales
- EBITDA is expected to reach upper end of forecasted range
 - Concentration on high-margin products supports EBITDA
 - A further slight reduction of energy and raw material costs will lead to increased EBITDA
- All other assumptions for Outlook 2023 are still valid
- The occurrence of a longer global recession is not part of this outlook.

FINANCIAL CALENDAR

Upcoming dates*



| | | |
|-------------|------|--|
| SEP 18 | 2023 | Baader Investment Conference 2023 |
| SEP 20 | 2023 | Berenberg and Goldman Sachs German Corporate Conference 2023 |
| OCT 19 | 2023 | Warburg "Klein aber fein" Konferenz 2023 |
| OCT 26 | 2023 | Quarterly Statement 3rd Quarter 2023 |
| NOV 15 | 2023 | Münchner Kapitalmarkt Konferenz 2023 |
| NOV 27 – 29 | 2023 | Deutsches Eigenkapitalforum 2023 |

*subject to change

**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q2 2023

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




| ALZCHEM GROUP (IN T€) | 31.12.2022 | 30.06.2023 | Deviation | |
|---|----------------|----------------|---------------|--------------|
| Intangible assets | 2,954 | 3,038 | 84 | 2.8% |
| Tangible assets | 181,526 | 176,826 | -4,701 | -2.6% |
| Investment properties | | | | |
| Right of use (assets) | 6,250 | 5,476 | -774 | -12.4% |
| Investments accounted for using the equity method | | | | |
| Financials assets | 6 | 6 | | |
| Trade receivables | | | | |
| Other receivables | 1,531 | 1,455 | -76 | -5.0% |
| <i>there of Deferred tax assets for pensions provisions</i> | | | | |
| Deferred tax assets | 15,956 | 16,634 | 678 | 4.2% |
| SUM NON-CURRENT ASSETS | 208,223 | 203,434 | -4,789 | -2.3% |
| Inventories | 122,404 | 126,492 | 4,088 | 3.3% |
| Trade receivables | 55,712 | 54,636 | -1,076 | -1.9% |
| Financial assets | 5,228 | 3,066 | -2,162 | -41.4% |
| Other receivables | 19,743 | 19,741 | -2 | 0.0% |
| Income tax receivables | 2,307 | 2,566 | 259 | 11.2% |
| Cash and cash equivalents | 9,243 | 9,299 | 56 | 0.6% |
| Assets classified as held for sale | | | | |
| Other assets | | | | |
| SUM CURRENT ASSETS | 214,638 | 215,800 | 1,163 | 0.5% |
| SUM ASSETS | 422,860 | 419,234 | -3,626 | -0.9% |

| ALZCHEM GROUP (IN T€) | 31.12.2022 | 30.06.2023 | Deviation | |
|---|----------------|----------------|----------------|---------------|
| Share capital | 101,763 | 101,763 | | |
| RETAINED EARNINGS (+) / LOSS (-) | 121,044 | 125,223 | 4,180 | 3.5% |
| Other comprehensive income | -15,316 | -17,194 | -1,878 | 12.3% |
| Own shares | -1,009 | | 1,009 | -100.0% |
| SHARE TO THE SHAREHOLDERS | 144,012 | 146,314 | 2,302 | 1.6% |
| Non-controlling interests | 1,934 | 2,020 | 85 | 4.4% |
| SUM EQUITY | 145,947 | 148,334 | 2,387 | 1.6% |
| Provisions for pensions | 90,141 | 92,542 | 2,402 | 2.7% |
| Other provisions | 17,011 | 17,731 | 720 | 4.2% |
| Loans | 27,498 | 53,081 | 25,584 | 93.0% |
| Finance lease liabilities | 4,622 | 4,008 | -614 | -13.3% |
| Trade liabilities | | | | |
| Other liabilities | 171 | | -171 | -100.0% |
| Deferred tax liabilities | 5,365 | 5,755 | 390 | 7.3% |
| SUM NON-CURRENT LIABILITIES | 144,808 | 173,118 | 28,310 | 19.6% |
| Other provisions | 1,944 | 2,343 | 399 | 20.5% |
| Loans | 66,408 | 21,788 | -44,620 | -67.2% |
| Finance lease liabilities | 1,707 | 1,593 | -114 | -6.7% |
| Finance liabilities | | | | |
| Trade liabilities | 37,386 | 38,709 | 1,323 | 3.5% |
| Other liabilities | 23,060 | 29,664 | 6,603 | 28.6% |
| Income tax liabilities | 1,602 | 3,686 | 2,085 | 130.2% |
| SUM CURRENT LIABILITIES | 132,106 | 97,782 | -34,324 | -26.0% |
| Sum EQUITY AND LIABILITIES | 422,860 | 419,234 | -3,626 | -0.9% |

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Adjustment of market interest rate from 3.7% → 3.6%; increasing impact on provision
- Stable development of expected pension trend at 2.25% (long term inflation expectations)
- Stable development of expected salary trend at 3.0%
- Moderately increasing cash payments

INCOME STATEMENT

Alzchem Group



| ALZCHEM GROUP (IN T€) | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Deviation (Q2) | |
|---|---------------|---------------|---------------|---------------|---------------|---------------|------------|------------|----------------|--------------|
| Revenue | 129,395 | 140,435 | 139,193 | 133,200 | 150,432 | 126,599 | | | -13,836 | -10% |
| Increase (+) / Decrease (-) in inventories of finished goods and work in progress | 14,144 | 14,467 | -1,959 | -4,459 | 916 | 9,105 | | | -5,361 | -37% |
| Other income | 4,070 | 5,736 | 5,955 | 8,416 | 5,574 | 1,906 | | | -3,830 | -67% |
| Raw materials and consumables used | -73,537 | -74,027 | -75,308 | -66,006 | -76,159 | -62,374 | | | 11,653 | -16% |
| Employee benefits expense | -34,000 | -36,287 | -31,316 | -35,537 | -35,262 | -36,012 | | | 275 | -1% |
| Other expense | -23,003 | -32,517 | -24,418 | -21,198 | -26,583 | -21,352 | | | 11,165 | -34% |
| EBITDA | 17,070 | 17,807 | 12,149 | 14,416 | 18,917 | 17,872 | | | 65 | 0% |
| Depreciation expense | -6,305 | -6,299 | -6,324 | -6,616 | -6,320 | -6,335 | | | -37 | 1% |
| Impairment | | | | | | | | | | |
| EBIT | 10,765 | 11,508 | 5,825 | 7,800 | 12,598 | 11,537 | | | 29 | 0% |
| Investment income | | | | | | | | | | |
| Other interest and similar income | 1,181 | 2,393 | 2,466 | 2,380 | 49 | 106 | | | -2,288 | -96% |
| Other interest and similar expense | -603 | -643 | -753 | -1,037 | -1,882 | -1,661 | | | -1,017 | 158% |
| Financial result | 578 | 1,750 | 1,713 | 1,343 | -1,832 | -1,555 | | | -3,305 | -189% |
| Result from associates | | | | | | | | | | |
| Result from ordinary business | 11,343 | 13,258 | 7,538 | 9,143 | 10,765 | 9,982 | | | -3,277 | -25% |
| Taxes on income and profit | -3,603 | -3,629 | -1,559 | -2,269 | -3,055 | -2,742 | | | 887 | -24% |
| <i>thereof income tax</i> | -2,520 | -2,094 | -842 | 562 | -2,946 | -2,716 | | | -622 | 30% |
| <i>thereof change from deferred taxes</i> | -1,082 | -1,535 | -717 | -2,831 | -109 | -26 | | | 1,509 | -98% |
| Annual result | 7,740 | 9,630 | 5,979 | 6,874 | 7,710 | 7,240 | | | -2,390 | -25% |
| <i>thereof minority interests</i> | 43 | 43 | 43 | 43 | 43 | 43 | | | | |
| <i>thereof shares held by shareholders</i> | 7,698 | 9,587 | 5,936 | 6,831 | 7,667 | 7,197 | | | -2,390 | -25% |
| Result per share in EUR | 0.76 € | 0.95 € | 0.59 € | 0.67 € | 0.75 € | 0.71 € | | | | |

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

| | |
|---|--|
| Revenue | |
| Increase (+) / Decrease (-) in inventories of finished goods and work in progress | |
| Other income | |
| Raw materials and consumables used | |
| Employee benefits expense | |
| Other expense | |
| EBITDA | |
| Depreciation expense | |
| Impairment | |
| EBIT | |
| Investment income | |
| Other interest and similar income | |
| Other interest and similar expense | |
| Financial result | |
| Result from associates | |
| Result from ordinary business | |
| Taxes on income and profit | |
| <i>thereof income tax</i> | |
| <i>thereof change from deferred taxes</i> | |
| Annual result | |
| <i>thereof minority interests</i> | |
| <i>thereof shares held by shareholders</i> | |
| Result per share in EUR | |

| Q2 2022 | Q2 2023 | Deviation (QoQ) | |
|---------------|---------------|-----------------|----------------|
| 140,435 | 126,599 | -13,836 | -9.9% |
| 14,467 | 9,105 | -5,361 | -37.1% |
| 5,736 | 1,906 | -3,830 | -66.8% |
| -74,027 | -62,374 | 11,653 | -15.7% |
| -36,287 | -36,012 | 275 | -0.8% |
| -32,517 | -21,352 | 11,165 | -34.3% |
| 17,807 | 17,872 | 65 | 0.4% |
| -6,299 | -6,335 | -37 | 0.6% |
| 0 | 0 | 0 | |
| 11,508 | 11,537 | 29 | 0.2% |
| 0 | 0 | 0 | |
| 2,393 | 106 | -2,288 | -95.6% |
| -643 | -1,661 | -1,017 | 158.2% |
| 1,750 | -1,555 | -3,305 | -188.8% |
| 0 | 0 | 0 | |
| 13,258 | 9,982 | -3,277 | -24.7% |
| -3,629 | -2,742 | 887 | -24.4% |
| -2,094 | -2,716 | -622 | 29.7% |
| -1,535 | -26 | 1,509 | -98.3% |
| 9,630 | 7,240 | -2,390 | -24.8% |
| 43 | 43 | 0 | 0.0% |
| 9,587 | 7,197 | -2,390 | -24.9% |
| 0.95 € | 0.71 € | 0 | -24.5% |

| YTD Jun.2022 | YTD Jun.2023 | Deviation (YoY) | |
|-----------------|-----------------|-----------------|----------------|
| 269,830 | 277,031 | 7,201 | 2.7% |
| 28,611 | 10,021 | -18,590 | -65.0% |
| 9,806 | 7,480 | -2,326 | -23.7% |
| -147,563 | -138,533 | 9,030 | -6.1% |
| -70,286 | -71,274 | -988 | 1.4% |
| -55,520 | -47,935 | 7,585 | -13.7% |
| 34,876 | 36,789 | 1,913 | 5.5% |
| -12,604 | -12,655 | -51 | 0.4% |
| 0 | 0 | 0 | |
| 22,273 | 24,134 | 1,862 | 8.4% |
| 0 | 0 | 0 | |
| 3,575 | 155 | -3,420 | -95.7% |
| -1,246 | -3,542 | -2,296 | 184.3% |
| 2,329 | -3,387 | -5,716 | -245.5% |
| 0 | 0 | 0 | |
| 24,601 | 20,747 | -3,854 | -15.7% |
| -7,231 | -5,797 | 1,434 | -19.8% |
| -4,614 | -5,662 | -1,048 | 22.7% |
| -2,617 | -135 | 2,482 | -94.8% |
| 17,370 | 14,950 | -2,420 | -13.9% |
| 85 | 85 | 0 | 0.0% |
| 17,285 | 14,865 | -2,420 | -14.0% |
| 1.71 € | 1.46 € | 0 | -14.1% |

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

| | Q2 2022 | Q2 2023 | 1 - 6 2022 | 1 - 6 2023 |
|--|----------------|----------------|----------------|----------------|
| Consolidated earnings before taxes | 13,258 | 9,982 | 24,601 | 20,747 |
| Depreciation on fixed and intangible assets | 6,299 | 6,335 | 12,604 | 12,655 |
| Decrease in pension provisions | -364 | -403 | -878 | -967 |
| Loss (+) / Profit (-) from the sale of non-current assets | -48 | 0 | -58 | -1 |
| Other non-cash income (-) and expenses (+) | 306 | 1,454 | 1,835 | 2,914 |
| Financial result | -1,750 | 1,555 | -2,329 | 3,387 |
| Interests & Taxes | -2,044 | -2,776 | -3,789 | -5,446 |
| Increase (+) / Decrease (-) Net Working Capital | -27,244 | 13,423 | -49,156 | 6,524 |
| Cashflow from ongoing operations (Net cash flow) | -11,588 | 29,570 | -17,169 | 39,814 |
| Cash outflows for investments in fixed assets | -7,720 | -3,768 | -15,082 | -8,577 |
| Cash inflows from the sale of fixed assets | 48 | 29 | 61 | 1 |
| Cash inflows from the disposal of investments | | | | |
| Cashflow from investing activity | -7,672 | -3,739 | -15,021 | -8,577 |
| Free cashflow | -19,260 | 25,831 | -32,190 | 31,238 |
| Deposits (+) / Repayment (-) bank loans long-term | | | | 30,000 |
| Repayment of bank loans long-term | -2,514 | -2,514 | -5,462 | -5,027 |
| Deposits (+) / Repayment (-) from short-term financing lines | 34,044 | -10,791 | 50,662 | -44,033 |
| Dividend payments | -10,136 | -10,685 | -10,136 | -10,685 |
| Payment of reduction in leasing liabilities | -478 | -440 | -941 | -896 |
| Payments for the acquisition of own shares (incl. transaction costs) | | | | |
| Payments to non-controlling interests | | | -171 | -171 |
| Cashflow from financing activity | 20,917 | -24,430 | 33,953 | -30,812 |
| Net increase / decrease in cash and cash equivalents | 1,657 | 1,401 | 1,763 | 426 |

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES

| SALES | 2021 | | | | 2022 | | | | 2023 | | | | Deviation PY (Q2) | |
|------------------------|----------------|----------------|---------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------|----------|-------------------|-------------|
| | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | T€ | % |
| Basics & Intermediates | 41,070 | 45,178 | 42,465 | 47,561 | 57,441 | 57,927 | 59,557 | 52,614 | 57,337 | 46,038 | | | -11,889 | -21% |
| Specialty Chemicals | 56,775 | 59,330 | 47,116 | 57,279 | 65,279 | 76,214 | 72,967 | 73,902 | 85,783 | 73,172 | | | -3,042 | -4% |
| Other and Holding | 6,477 | 6,492 | 6,339 | 6,212 | 6,675 | 6,294 | 6,670 | 6,684 | 7,312 | 7,389 | | | 1,095 | 17% |
| Group Consolidation | | | | | | | | | | | | | | |
| Alzchem Group | 104,321 | 111,000 | 95,920 | 111,052 | 129,395 | 140,435 | 139,193 | 133,200 | 150,432 | 126,599 | | | -13,836 | -10% |

EBITDA

| EBITDA | 2021 | | | | 2022 | | | | 2023 | | | | Deviation PY (Q2) | |
|------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|----------|----------|-------------------|-----------|
| | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | T€ | % |
| Basics & Intermediates | 2,791 | 3,826 | 3,118 | 1,250 | 2,841 | 853 | -2,621 | 3,910 | 2,780 | 2,410 | | | 1,556 | 182% |
| Specialty Chemicals | 13,947 | 14,801 | 10,096 | 11,820 | 14,267 | 16,322 | 14,637 | 7,789 | 16,019 | 14,936 | | | -1,386 | -8% |
| Other and Holding | 435 | -43 | 512 | 502 | -139 | 830 | 1,038 | 230 | 475 | 438 | | | -391 | -47% |
| Group Consolidation | -451 | 409 | 112 | -1,079 | 103 | -200 | -905 | 2,487 | -357 | 88 | | | 288 | 144% |
| Alzchem Group | 16,722 | 18,993 | 13,838 | 12,493 | 17,072 | 17,805 | 12,149 | 14,416 | 18,917 | 17,872 | | | 67 | 0% |

EXECUTIVE TEAM

Alzchem Group AG



ANDREAS NIEDERMAIER

CEO

BEI ALZCHEM SEIT 1999

RESSORTVERANTWORTUNG

Finanzen & Controlling,
Unternehmensstrategie, Investor
Relations & Kommunikation, Risk
Management, Personal, IT, Supply
Chain Management,
Recht/Patente & Marken

DR. GEORG WEICHSELBAUMER

CSO

BEI ALZCHEM SEIT 2012

RESSORTVERANTWORTUNG

Marketing, Vertrieb,
Innovationsmanagement &
Verfahrensentwicklung, F&E,
Produktsicherheit /-zulassung

KLAUS ENGLMAIER

COO

BEI ALZCHEM SEIT 1988

RESSORTVERANTWORTUNG

Produktion, Engineering,
Umweltschutz/Sicherheit/Ges
undheit/Qualität, Technik


ALZCHEM GROUP LOCATIONS

Production sites and sales companies



“VERBUND” – FULLY INTEGRATED BUSINESS MODEL

Benefits of the “Verbund” system approach



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS



POPULATION
GROWTH



LONGER LIFE
EXPECTANCY



CLIMATE
CHANGE



SUSTAINABILITY

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries







| MAIN PRODUCTS | | DESCRIPTION | END-MARKETS |
|------------------------|--|--|--|
| SPECIALTY CHEMICALS | | A nutritional additive for poultry and pigs | Feed additive |
| | | Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition | Food supplements |
| | | Dietary supplement with pure creatine | Food supplements |
| | | Creatine for health and food applications | Food supplements |
| | | Plant growth regulator used in fruit production | Agriculture |
| | | Additive for plant protection formulations | Agriculture |
| | | Plant growth regulator used in fruit production | Agriculture |
| | | Biocide for the prevention of diseases in animal production | Agriculture |
| | | Silicon nitride powder for ceramic applications | Ceramics |
| | | Highly purified form of guanidine salts | Pharmaceuticals / API |
| | | An organic compound widely used in agriculture and pharmaceuticals | Agriculture and pharmaceuticals |
| | | Hardeners and accelerators in powder, paste and liquid form | Hardener & Accelerator Systems for Composite Materials |
| | | Various applications incl. flotation agents and pharmaceutical raw materials | Mining and pharmaceuticals |
| | | Intermediates for agrochemical products | Various |

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



| | MAIN PRODUCTS | DESCRIPTION | END-MARKETS |
|------------------------|--|---|-------------------------------|
| BASICS & INTERMEDIATES |  | Calcium carbide-based mixtures for hot metal desulphurization | Steel industry |
| | Guanidine Salts | Fuel for airbags, key production of the intermediate product | Automotive |
| | Dicyandiamide | Versatile intermediate in various markets including the pharmaceutical industry | Pharmaceutical Agriculture |
| |  | Business fields in color, agro and pharmaceutical applications | Pigments Pharmaceutical |
| |  | Reduction of methane emissions during storage of manure | Agriculture |
| |  | Special calcium cyanamide multi-effect fertilizer | Agriculture |
| OTHER & HOLDING | Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, MBCC Group, Firmenich, Aramark, VIActiv) | | |
| | Site services | | |
| | Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments | | |


KEY SHARE DATA

Share Details as of August 1, 2023



| | |
|-----------------------|---|
| SHARES OUTSTANDING | 10,176,335 |
| LAST CLOSING PRICE | EUR 18.95 |
| MARKET CAPITALIZATION | EUR 192.8 m |
| TICKER | ACT |
| WKN | A2YNT3 |
| ISIN | DE000A2YNT30 |
| LISTING | Frankfurt Stock Exchange – Prime Standard |
| DESIGNATED SPONSOR | Baader Bank AG Oddo Seydler Bank AG |

SHAREHOLDER STRUCTURE



As of April 2023. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the "Guide to the DAX Equity Indices".